The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Inducing and exploiting vulnerabilities for the treatment of liver cancer
Open accessAbstract
Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies 1,2; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma 3. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis)4,5. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition 6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescence induction by inhibition of DNA replication kinase CDC7 has also been paired with a senolytic that disrupts mTOR signaling, inducing apoptosis in senescent human liver cancer cells and improving survival in mouse models of HCC (Wang et al. 2019).”
From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Wang et al. 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, many of the genes have been denoted as possible therapeutic targets in a variety of epithelial-based cancers, such as CDC7 in oral squamous carcinoma30 and liver cancer31, ATP1B3 in gastric cancer32, and FKBP14 in ovarian cancer33.”
From Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature (2023) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse model of liver cancer, the mTOR inhibitor AZD8055 also showed senolytic potential against cancer cells with senescence induced by small- molecule inhibitors of CDC7 (ref. 207 ) .”
From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [207]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Elevated expression of p16 in melanocytes156 and epidermal and dermal cells157,158 is associated with human aging.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [156]
Experimental — accuracy not yet measuredIn the citing paper
“Based on the preclinical experimental evidence enumerated here, approaches based on the induction of senescence in large fraction of tumors have the potential to enter the realm of the clinical practice, even more if combined with adjuvant immunotherapy or senolytic therapy to remove potentially harmful senescent escaper variants, as recently proposed.189,202,203”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [202]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citationThe comet assay: a method to measure DNA damage in individual cells
Olive, P. L., & Banáth, J. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.5 · Cited by 1,845
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Cited by
Sorted by citations
Items 101–200 of 432
Cellular senescence in cancer: molecular mechanisms and therapeutic targets
Jin, P., Duan, X., Li, L., Zhou, P., Zou, C., & Xie, K. (2024) · MedComm · doi:10.1002/mco2.542 · Cited by 51
Shi, D., Hu, L., Li, X., Liu, W., Gao, Y. J., Li, X., Jiang, B., Xia, C., Guo, Y., & Li, J. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.128302 · Cited by 44
Guo, Y., Wang, J., Benedict, B., Yang, C. G., van Gemert, F. P. A., Ma, X., Gao, D., Wang, H., Zhang, S., Lieftink, C., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00981-0 · Cited by 45
Self-citationMa, X., Sun, P., & Gong, M. (2020) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2020.3004808 · Cited by 43
Ramirez, C. F. A., Taranto, D., Ando‐Kuri, M., de Groot, M. H. P., Tsouri, E., Huang, Z., de Groot, D., Kluin, R. J. C., Kloosterman, D. J., Verheij, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46835-2 · Cited by 42
Self-citationCellular senescence: from anti-cancer weapon to anti-aging target
Yuan, L., Alexander, P. B., & Wang, X. (2020) · Science China Life Sciences · doi:10.1007/s11427-019-1629-6 · Cited by 42
Hierarchical Hydrogels with Ordered Micro-Nano Structures for Cancer-on-a-Chip Construction
Zhu, L., Shao, C., Chen, H., Chen, Z., & Zhao, Y. (2021) · Research · doi:10.34133/2021/9845679 · Cited by 41
Human-correlated genetic models identify precision therapy for liver cancer
Müller, M., May, S., Hall, H., Kendall, T. J., McGarry, L., Blukacz, L., Nuciforo, S., Γεωργακοπούλου, Α., Jamieson, T., Phinichkusolchit, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08585-z · Cited by 40
Cellular senescence in liver diseases: From molecular drivers to therapeutic targeting
Du, K., Umbaugh, D. S., Ren, N., & Diehl, A. M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.021 · Cited by 42
CRISPR screen in mechanism and target discovery for cancer immunotherapy
Liu, D., Zhao, X., Tang, A., Xu, X., Liu, S., Zha, L., Ma, W., Zheng, J., & Shi, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188378 · Cited by 44
Stress response decay with aging visualized using a dual-channel logic-based fluorescent probe
Tian, J., Shi, D., Zhang, Y., Li, X., Li, X., Teng, H. W., James, T. D., Li, J., & Guo, Y. (2021) · Chemical Science · doi:10.1039/d1sc04162b · Cited by 38
Senescent cells at the crossroads of aging, disease, and tissue homeostasis
Kuehnemann, C., & Wiley, C. D. (2023) · Aging Cell · doi:10.1111/acel.13988 · Cited by 44
Senescence of Tumor Cells in Anticancer Therapy—Beneficial and Detrimental Effects
Piskorz, W. M., & Cechowska‐Pasko, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911082 · Cited by 39
Uceda-Castro, R., Margarido, A. S., Cornet, L., Vegna, S., Hahn, K., Song, J., Putavet, D. A., van Geldorp, M., Çitirikkaya, C. H., de Keizer, P. L. J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100821 · Cited by 40
Self-citationD-galactose induces senescence of glioblastoma cells through YAP-CDK6 pathway
Xu, X., Shen, X., Feng, W., Yang, D., Jin, L., Wang, J., Wang, M., Ting, Z., Xue, F., Zhang, J., et al. (2020) · Aging · doi:10.18632/aging.103819 · Cited by 40
Song, L., Luo, Y., Li, S., Hong, M., Wang, Q., Chi, X., & Yang, C. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s270124 · Cited by 38
Peschke, K., Jakubowsky, H., Schäfer, A., Maurer, H. C., Lange, S., Orben, F., Bernad, R., Harder, F. N., Eiber, M., Öllinger, R., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114876 · Cited by 37
Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies
Fakhri, S., Moradi, S. Z., DeLiberto, L. K., & Bishayee, A. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114989 · Cited by 39
Saavedra-García, P., Román-Trufero, M., Al-Sadah, H. A., Blighe, K., López-Jiménez, E. A., Christoforou, M., Penfold, L., Capece, D., Xiong, X., Miao, Y., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018229118 · Cited by 39
Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Sahu, A. D., Wang, X., Munson, P. B., Klomp, J. P. G., Wang, X., Gu, S. S., Qian, G., Nicol, P., Zeng, Z., Wang, C., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0244 · Cited by 35
Self-citationTargeting senescent cells to reshape the tumor microenvironment and improve anticancer efficacy
Jiang, B., Zhang, W., Zhang, X., & Sun, Y. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.05.002 · Cited by 39
Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
Wu, X., Ma, W., Mei, C., Chen, X., Yao, Y., Liu, Y., Qin, X., & Yuan, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01603-0 · Cited by 36
Chen, X., Cheng, D., Ding, M., Yu, N., Liu, J., Li, J., & Lin, L. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb00872f · Cited by 35
TRIM22 induces cellular senescence by targeting PHLPP2 in hepatocellular carcinoma
Kang, D., Hwang, H. J., Baek, Y., Sung, J. Y., Kim, K., Park, H. J., Ko, Y., Kim, Y.-N., & Lee, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06427-w · Cited by 36
Cellular senescence offers distinct immunological vulnerabilities in cancer
Zhou, L., Ma, B., & Ruscetti, M. A. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.11.010 · Cited by 40
Targeting senescent cells for the treatment of age-associated diseases
Suda, M., Tchkonia, T., Kirkland, J. L., & Minamino, T. (2024) · The Journal of Biochemistry · doi:10.1093/jb/mvae091 · Cited by 38
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32
Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology
Menéndez, J. A., Cuyàs, E., Encinar, J. A., Steen, T. V., Verdura, S., Llop‐Hernández, À., López, J., Serrano‐Hervás, E., Osuna, S., Martín-Castillo, B., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13582 · Cited by 41
Yang, C. G., Chen, J., Li, Y., Huang, X., Liu, Z., Wang, J., Jiang, H., Qin, W., Lv, Y., Wang, H., et al. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa295 · Cited by 31
Self-citationWang, Y., Cheng, C., Lu, Y., Lian, Z., Liu, Q., Xu, Y., Li, Y., Li, H., Zhang, L., Jiang, X., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-0673 · Cited by 30
Zhang, Y., Xiao, B., Yuan, S., Ding, L., Pan, Y., Jiang, Y., Sun, S., Ke, X., Cai, L., & Jia, L. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103323 · Cited by 30
Dong, F., He, K., Zhang, S., Song, K., Jiang, L., Hu, L.-P., Li, Q., Zhang, X., Zhang, N., Li, B.-T., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114818 · Cited by 37
Self-citationWang, X., Jowsey, W. J., Cheung, C., Smart, C. J., Klaus, H. R., Seeto, N. E. J., Waller, N. J. E., Chrisp, M. T., Peterson, A. L., Ofori-Anyinam, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54072-w · Cited by 28
Deng, F., Chen, D., Wei, X., Lu, S., Luo, X., He, J., Liu, J., Meng, T., Yang, A., & Chen, H. (2020) · Aging · doi:10.18632/aging.102820 · Cited by 30
Therapy-induced senescent tumor cells in cancer relapse
Song, K., Wang, J., & Huang, D. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.09.001 · Cited by 33
Senolytics: charting a new course or enhancing existing anti-tumor therapies?
Czajkowski, K., Herbet, M., Murias, M., & Piątkowska‐Chmiel, I. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01018-5 · Cited by 35
Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma
Tang, L., Chen, R., & Xu, X. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.016 · Cited by 30
Mapping the Landscape of Synthetic Lethal Interactions in Liver Cancer
Chen, Y., Guo, Y., Qian, R., Huang, Y., Zhang, L., Wang, J., Huang, X., Liu, Z., Qin, W., Wang, C., et al. (2021) · Theranostics · doi:10.7150/thno.63416 · Cited by 29
Self-citationCellular Senescence in Hepatocellular Carcinoma: The Passenger or the Driver?
Cai, X., Guillot, A., & Liu, H. (2022) · Cells · doi:10.3390/cells12010132 · Cited by 31
Yang, X., Wang, X., Hu, L.-P., Feng, M., Zhou, Y.-Q., Li, D., Li, J., Miao, X.-C., Zhang, Y., Yao, L.-L., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.029 · Cited by 27
Wang, J., Zhou, X., Yu, P., Yao, J., Guo, P., Xu, Q., Zhao, Y., Wang, G., Li, Q., Zhu, X., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00886-2 · Cited by 28
Self-citationGolonka, R. M., & Vijay–Kumar, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.10.004 · Cited by 28
Cancer Grand Challenges: Embarking on a New Era of Discovery
Foulkes, I., & Sharpless, N. E. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1657 · Cited by 27
Giannakoulis, V. G., Dubovan, P., Papoutsi, E., Kataki, A., & Koskinas, J. S. (2021) · Cancers · doi:10.3390/cancers13184732 · Cited by 27
The Expression of the Senescence-Associated Biomarker Lamin B1 in Human Breast Cancer
Saleh, T., Alhesa, A., El‐Sadoni, M., Shahin, N. A., Alsharaiah, E., Shboul, S. A., Awad, H., Bloukh, S., Al-Balas, M., Alsalem, M., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12030609 · Cited by 28
From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs
L’Hôte, V., Mann, C., & Thuret, J. (2022) · Open Biology · doi:10.1098/rsob.220171 · Cited by 27
Counteracting Immunosenescence—Which Therapeutic Strategies Are Promising?
Hieber, C., Grabbe, S., & Bros, M. (2023) · Biomolecules · doi:10.3390/biom13071085 · Cited by 30
Liu, S., Meng, Y., Zhang, Y., Qiu, L., Wan, X., Yang, X., Zhang, Y., Liu, X., Wen, L., Lei, X., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.04.007 · Cited by 28
The dual role of cellular senescence in human tumor progression and therapy
Ma, L., Yu, J., Fu, Y., He, X., Ge, S., Jia, R., Zhuang, A., Yang, Z. H., & Fan, X. (2024) · MedComm · doi:10.1002/mco2.695 · Cited by 30
Molecular Mechanisms to Target Cellular Senescence in Hepatocellular Carcinoma
Mittermeier, C., Konopa, A., & Muehlich, S. (2020) · Cells · doi:10.3390/cells9122540 · Cited by 27
The Quest to Define and Target Cellular Senescence in Cancer
Wang, B., & Demaria, M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-2032 · Cited by 26
Exploiting aneuploidy-imposed stresses and coping mechanisms to battle cancer
Zhou, L., Jilderda, L. J., & Foijer, F. (2020) · Open Biology · doi:10.1098/rsob.200148 · Cited by 30
Yang, P., Lian, Q., Fu, R., Ding, G., Amin, S., Li, Z., & Li, Z. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c07952 · Cited by 25
Liu, S., Zhang, Y., Qiu, L., Zhang, S., Meng, Y., Huang, C., Chen, Z., Zhang, B., & Han, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.861000 · Cited by 26
Okamura, K., Sato, M., Suzuki, T., & Nohara, K. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116231 · Cited by 26
Chen, J., Xu, Z., Huang, H., Tang, Y., Shan, H., & Xiao, F. (2023) · JCI Insight · doi:10.1172/jci.insight.168375 · Cited by 25
Baú-Carneiro, J. L., Sumida, I. A. G., GALLON, M., Zaleski, T., Bóia-Ferreira, M., & Cavassin, F. B. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101303 · Cited by 25
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
Digiacomo, G., Fumarola, C., Monica, S. L., Bonelli, M. A., Cavazzoni, A., Galetti, M., Terenziani, R., Eltayeb, K., Volta, F., Zoppi, S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942341 · Cited by 24
Zhou, Y., Wang, S., Wu, W., Jing, L., Li, H., Jia, Q., Zheng, J., Zheng, X., Yu, R., Wu, Q., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104397 · Cited by 24
Self-citationSenescence and senolysis in cancer: The latest findings
Imawari, Y., & Nakanishi, M. (2024) · Cancer Science · doi:10.1111/cas.16184 · Cited by 25
Therapy-Induced Senescence: Novel Approaches for Markers Identification
Pacifico, F., Magni, F., Leonardi, A., & Crescenzi, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158448 · Cited by 25
Hao, W., Chen, Z., Tang, J., Ru, Y., Gao, W., & Xu, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04704-4 · Cited by 24
Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets
Zheng, P., Yan, W., Ding, Y.-N., Zhang, Y., Chen, Z., Qian, J., & Ge, J. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02630-7 · Cited by 26
Hong, X., Luo, H., Zhu, G., Guan, X., Jia, Y., Yu, H., Lv, X., Yu, T., Lan, H., Zhang, Q., et al. (2020) · Journal of Cancer · doi:10.7150/jca.44788 · Cited by 22
Mechanisms of cancer stem cell senescence: Current understanding and future perspectives
Zhang, D., Monteiro, M. J., Liu, J., & Gu, W. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13528 · Cited by 25
FBXW7 inactivation induces cellular senescence via accumulation of p53
Gong, L., Cui, D., Liu, D., Shen, X. Z., Pan, H., Xiong, X., & Zhao, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05229-2 · Cited by 22
The Dynamic Process and Its Dual Effects on Tumors of Therapy-Induced Senescence
Liao, C., Xiao, Y., & Liu, L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s285083 · Cited by 24
Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies
Feucht, J., & Abou‐El‐Enein, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.011 · Cited by 22
Dynamic Aging: Channeled Through Microenvironment
Tan, Q., Liang, N., Zhang, X., & Li, J. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.702276 · Cited by 25
Jin, Y., Yang, R., Ding, J., Zhu, F., Zhu, C., Xu, Q., & Cai, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.09.009 · Cited by 21
Segeren, H. A., van Liere, E. A., Riemers, F. M., de Bruin, A., & Westendorp, B. (2022) · Oncogene · doi:10.1038/s41388-022-02291-0 · Cited by 21
Morita, T., Yu, J., Kashima, Y., Kamata, R., Yamamoto, G., Minamide, T., Mashima, C., Yoshiya, M., Sakae, Y., Yamauchi, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43274-3 · Cited by 21
Chen, L., Sun, R., & Fang, K. (2024) · Pathology International · doi:10.1111/pin.13403 · Cited by 21
Breaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy
Liu, Y., Park, S., & Li, Y. (2025) · Cancers · doi:10.3390/cancers17121941 · Cited by 21
Drug Repurposing in Oncology: Current Evidence and Future Direction
Zhang, Z., Ji, J., & Liu, H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200820124111 · Cited by 20
Luo, S., Liang, C., Zhang, Q., & Zhang, P. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.07.009 · Cited by 20
Spanjaard, A., Shah, R., de Groot, D., Buoninfante, O. A., Morris, B., Lieftink, C., Pritchard, C. E. J., Zürcher, L. M., Ormel, S., Catsman, J. J. I., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac545 · Cited by 20
Self-citationYang, S., Li, A., Lv, L., Zheng, Z., Liu, P., Min, J., & Wei, J. (2024) · Journal of Cancer · doi:10.7150/jca.96500 · Cited by 19
Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics
Yang, Y., Qu, Y., Li, Z., Tan, Z., Lei, Y., & Bai, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.874805 · Cited by 19
Feng, N., Du, X.-Y., Zhang, Y.-S., Jiao, Z.-K., Wu, X., & Yang, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1061091 · Cited by 20
Yu, S., Zhao, R., Zhang, B., Lai, C., Li, L., Shen, J., Tan, X., & Shao, J. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100828 · Cited by 18
Therapy-induced senescence — an induced synthetic lethality in liver cancer?
Wolter, K., & Zender, L. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0262-3 · Cited by 18
Tian, X., Li, J., Zhang, Y., Gao, Y. J., Afzal, M. W., Wang, A., James, T. D., Bai, Y., & Guo, Y. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.131618 · Cited by 18
Mitochondrial priming and response to BH3 mimetics in “one-two punch” senogenic-senolytic strategies
López, J., Llop‐Hernández, À., Verdura, S., Serrano‐Hervás, E., Martinez‐Balibrea, E., Bosch‐Barrera, J., Teixidor, E., López‐Bonet, E., Martín-Castillo, B., Josep Sardanyés, A., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02379-y · Cited by 20
Jiang, Z., Cheng, L., Wu, Z., Zhou, L., Wang, H., Hong, Q., Wu, Q., Long, Y., Huang, Y., Xu, G., et al. (2022) · EMBO Reports · doi:10.15252/embr.202154275 · Cited by 17
Yang, Z., Gao, S., Wong, C. C., Liu, W., Chen, H., Shang, H., Wu, Z. Y., Xu, L., Zhang, X., Wong, N., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6065 · Cited by 18
TRPM2 regulates cell cycle through the Ca2+-CaM-CaMKII signaling pathway to promote HCC
Cai, X., Yu, X., Yang, J., Lu, L., Hua, N., Duan, X., Ye, P., Ni, L., Jiang, L., Yang, W., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000101 · Cited by 17
Li, M., Sun, J., & Shi, G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1220376 · Cited by 20
Gains of 20q11.21 in human pluripotent stem cells: Insights from cancer research
Krivec, N., Ghosh, M. S., & Spits, C. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2023.11.013 · Cited by 20
Zhang, J., Guan, X., & Zhong, X. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.10.006 · Cited by 20
The bioactive ingredients in Actinidia chinensis Planch. Inhibit liver cancer by inducing apoptosis
Hong, Z., Lü, Y., Ran, C., Tang, P., Huang, J. W., Yang, Y., Duan, X., & Wu, H. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114553 · Cited by 17
Fu, R., Dou, Z., Li, N., Zhang, J., Li, Z., & Yang, P. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115021 · Cited by 17
CDC7 as a novel biomarker and druggable target in cancer
Liu, R., & Huang, Y. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02853-4 · Cited by 17
Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature
Scarborough, J. A., Eschrich, S. A., Torres-Roca, J., Dhawan, A., & Scott, J. G. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00375-y · Cited by 14
“Furthermore, many of the genes have been denoted as possible therapeutic targets in a variety of epithelial-based cancers, such as CDC7 in oral squamous carcinoma 30 and liver cancer 31 , ATP1B3 in gastric cancer 32 , and FKBP14 in ovarian cancer 33 .”
Senescence in cancer: Hallmarks, paradoxes, and therapeutic promise
Hinterleitner, C., Goldberg, H. V., McHugh, D., Barthet, V. J. A., Filliol, A. A., & Lowe, S. W. (2026) · Cell · doi:10.1016/j.cell.2026.03.005 · Cited by 20
Qing, Y., Li, H., Zhao, Y., Hu, P., Wang, X., Yu, X., Zhu, M., Wang, H., Wang, Z., Guo, Q., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5529518 · Cited by 18
Targeting Effect of Betulinic Acid Liposome Modified by Hyaluronic Acid on Hepatoma Cells In Vitro
Wu, X., Wei, Z., Feng, H., Chen, H., Xie, J., Huang, Y., Wang, M., Yao, C., & Huang, J. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.06.015 · Cited by 16
CSTF2 Promotes Hepatocarcinogenesis and Hepatocellular Carcinoma Progression via Aerobic Glycolysis
Chen, Z., Hao, W., Tang, J., Gao, W., & Xu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.897804 · Cited by 16
Kuboki, Y., Shimizu, T., Yonemori, K., Kojima, T., Kondo, S., Koganemaru, S., Iwasa, S., Harano, K., Koyama, T., Lu, V., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0277 · Cited by 16
Zhang, B., Ren, Z., Zheng, H., Lin, M., Chen, G., Luo, O. J., & Zhu, G. (2023) · iScience · doi:10.1016/j.isci.2023.106099 · Cited by 16
Metadata
- Authors
- Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., du Chatinier, A., Wang, L., Gao, D., Evers, B., Jin, G., Xue, Z., Schepers, A., Jochems, F., Sanchez, A. M., Mainardi, S., te Riele, H., Beijersbergen, R. L., Qin, W., Akkari, L., & Bernards, R.
- Affiliations
- Shanghai Jiao Tong University (CN)
- The Netherlands Cancer Institute (NL)
- Fudan University (CN)
- Corresponding author
- Qin, Wenxin
- Akkari, Leila
- Bernards, René
- ORCID
- Venue
- Nature
- Published
- 2019-10-02
- Volume
- 574
- Issue
- 7777
- Pages
- 268-272
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6858884
- OpenAlex
- W2977409903
- Cited by
- 427
- References
- 31
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 85 · 2023: 64 · 2022: 66 · 2021: 67 · 2020: 63
- FWCI
- 33.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- hepatocellular carcinoma, liver cancer, senescence, senolysis, TP53 mutation, sertraline, mTOR signaling, apoptosis, drug combination therapy, kinome screen, antidepressant repurposing
- MeSH terms
- Animals, Disease Models, Animal, Female, Liver Neoplasms, Male, Mice, Inbred BALB C, Mutation, Signal Transduction, Tumor Suppressor Protein p53, Cellular Senescence, Apoptosis, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Sertraline, Cell Line, Tumor, Mice, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
